Atopic Dermatitis Clinical Trials in San Antonio, Texas
10 recruitingSan Antonio, Texas
Showing 1–10 of 10 trials
Recruiting
Phase 2
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Atopic Dermatitis
Apogee Therapeutics, Inc.350 enrolled56 locationsNCT07003425
Recruiting
Phase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Enveda Therapeutics60 enrolled23 locationsNCT07298395
Recruiting
Phase 2
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
DermatitisAtopic DermatitisEczema Atopic Dermatitis+5 more
Apollo Therapeutics Ltd280 enrolled85 locationsNCT07599813
Recruiting
Phase 2
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Bluefin Biomedicine, Inc.225 enrolled88 locationsNCT07105488
Recruiting
Phase 2
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Kymera Therapeutics, Inc.200 enrolled67 locationsNCT07217015
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Hoffmann-La Roche160 enrolled73 locationsNCT06863961
Recruiting
Phase 2
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Atopic Dermatitis
Pfizer340 enrolled98 locationsNCT05995964
Recruiting
Phase 4
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
Atopic Dermatitis
Eli Lilly and Company200 enrolled66 locationsNCT07006792
Recruiting
Phase 3
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
AbbVie675 enrolled148 locationsNCT06461897
Recruiting
Phase 2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Novartis Pharmaceuticals224 enrolled99 locationsNCT06947993